Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
| Autoři | |
|---|---|
| Rok publikování | 2024 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | EUROSURVEILLANCE |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.8.2400089 |
| Doi | http://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089 |
| Klíčová slova | Influenza A vaccine effectiveness; European primary care; hospital multicentre studies |
| Popis | Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively. |